Key Takeaways
- Celea Therapeutics, founded by PureTech (LSE:PRTC), completed a $180 million financing round and dosed the first patient in its Phase 3 SURPASS-IPF trial within days of each other.
- The trial will compare deupirfenidone against standard-of-care pirfenidone across roughly 1,100 patients in more than 30 countries, with results expected in the second half of 2029.
- PureTech retains a 35.4% fully diluted stake in Celea, plus tiered royalties of 1-3% and up to $190 million in sales-linked milestone payments.
- PureTech reported cash and cash equivalents of $252.5 million at 31 December 2025, with management guiding to runway through at least the end of 2028.
- The company also disclosed its intention to voluntarily delist from Nasdaq , citing the London Stock Exchange as the primary venue for trading and Liquidity .
PureTech Health (LSE:PRTC), the London-listed biotech known for founding and spinning out drug-discovery companies, has reached one of the most consequential moments in its history. Celea Therapeutics, the company PureTech created to develop deupirfenidone for idiopathic pulmonary fibrosis (IPF), has completed a $180 million financing and dosed the first patient in a global Phase 3 trial. For a Business that has spent years explaining its "hub and spoke" model, this is the clearest evidence yet that the strategy can convert early science into externally funded, late-stage Drug Development .
What Happened
On 2 July 2026, PureTech announced that Celea Therapeutics had completed a $180 million financing round. Investors named include RA Capital Management, Leaps by Bayer, PureTech itself, a large US-based healthcare-focused fund, and a sovereign Wealth fund. Eleven days later, on 13 July, PureTech confirmed Celea had dosed the first patient in SURPASS-IPF, a global, randomised, double-blind Phase 3 trial evaluating deupirfenidone against pirfenidone, the current standard-of-care antifibrotic.
The trial is a head-to-head comparison rather than placebo-controlled: roughly 1,100 patients across more than 30 countries will receive either deupirfenidone (825mg three times daily) or pirfenidone (801mg three times daily) over 52 weeks, with the primary endpoint being change in forced vital capacity from baseline. Chief executive Robert Lyne called the trial's initiation "another important milestone for both PureTech and Celea," while Celea chief executive Sven Dethlefs pointed to the speed "from completing our financing to dosing the first patient" as evidence of extensive preparation.
Why It Matters
Deupirfenidone (also known as LYT-100) is a deuterated form of pirfenidone designed to improve tolerability while preserving, or improving, efficacy against the lung scarring that characterises IPF. There is no cure for the disease, and median survival after diagnosis is typically cited at two to five years. Existing antifibrotics, including pirfenidone, are often poorly tolerated, leading to dose reductions or discontinuation. If deupirfenidone can demonstrate meaningfully better tolerability alongside comparable or superior lung-function preservation, it could reposition treatment for a disease where Options remain limited.
For PureTech, the significance extends beyond the science. Its founded-entity model depends on proving that internally generated science can attract substantial third-party capital once it reaches an inflection point, reducing PureTech's own cash burn while preserving Equity upside. Celea's raise, and its swift progression into a pivotal trial, is the clearest real-world test of that thesis yet, following a similar path taken by Seaport Therapeutics, another founded entity now pursuing a public listing.
Latest Financial and Operational Performance
PureTech reported cash and cash equivalents of $252.5 million at 31 December 2025, plus short-term investments of $24.8 million, taking total consolidated liquidity to $277.3 million. By 31 March 2026, cash and cash equivalents had reduced to $248.1 million. Management has guided that operational runway extends at least through the end of 2028, and expects lower consolidated operating costs as development activity, and its funding burden, shifts increasingly to the founded-entity level following Celea's financing.
Alongside the IPF programme, PureTech's FY2025 annual results, published on 29 April 2026, highlighted positive topline data for LYT-200 in relapsed/refractory myeloid malignancies at Gallop Oncology, another wholly owned founded entity, and continued progress at Seaport Therapeutics, in which PureTech holds a 35% equity interest, including a filed S-1 registration statement. The same announcement disclosed PureTech's intention to voluntarily delist from Nasdaq, citing the LSE as the venue for the substantial majority of trading Volume , liquidity and price discovery.
Key Numbers
- $180 million: Celea Therapeutics financing completed 2 July 2026
- 35.4%: PureTech's ownership of Celea's fully diluted Share Capital post-financing
- ~1,100 patients, 30+ countries: scale of the Phase 3 SURPASS-IPF trial
- Second half of 2029: expected trial results
- $252.5 million: PureTech cash and cash equivalents at 31 December 2025
- $248.1 million: PureTech cash and cash equivalents at 31 March 2026
- Up to $190 million: milestone payments PureTech is entitled to from Celea, tied to sales thresholds, plus tiered royalties of 1–3% and 20% of any sublicense income
Growth Opportunities
PureTech's Economics in Celea extend beyond the equity stake. Alongside its 35.4% fully diluted ownership, PureTech retains tiered royalties of 1–3% on annual net sales, up to $190 million in sales-linked milestones, and 20% of any sublicense income. If deupirfenidone succeeds in SURPASS-IPF, that combination gives PureTech leveraged upside without carrying the full cost of late-stage development.
The broader pipeline offers further optionality. Seaport's S-1 filing points towards a public listing that would crystallise value from PureTech's 35% stake, while Gallop Oncology's positive LYT-200 data opens a path to external financing for trials in high-risk myelodysplastic syndrome, echoing the Celea playbook. Deupirfenidone also carries Orphan Drug Designation from the FDA and European Commission, and PureTech notes regulators have indicated a single well-designed Phase 3 trial, plus the totality of clinical data, could support US registration.
Risks Investors Should Know
SURPASS-IPF results are not expected until the second half of 2029, meaning shareholders face several years before the trial's outcome, and any commercial payoff, becomes clear. The head-to-head design against pirfenidone, rather than placebo, raises the bar for demonstrating superiority or better tolerability. PureTech's stake in Celea has already been diluted to 35.4%, and further raises to fund the trial could dilute it more. More broadly, PureTech remains a clinical-stage company with no product Revenue , dependent on continued value creation from founded entities to justify its own valuation.
What to Watch Next
Investors should watch for enrolment updates in SURPASS-IPF, any further Celea financing, progress on Seaport's potential public listing, and news on Gallop Oncology's financing for its myelodysplastic syndrome programme. PureTech's Nasdaq delisting process is also worth monitoring for its effect on the Shareholder base and liquidity.
Outlook
Celea's $180 million financing and the dosing of the first Phase 3 patient mark a genuine proof point for PureTech's founded-entity strategy, translating early science into externally capitalised, late-stage development. The prize, a differentiated therapy for a devastating lung disease, remains years away, and the path from here still carries clinical, financing and dilution risk. But for a company long asked to justify its model, this is tangible progress.
_11_18_2026_06_43_20_247880.jpg)





Please wait processing your request...